Status:
COMPLETED
Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL
Lead Sponsor:
AstraZeneca
Conditions:
Depression
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.
Eligibility Criteria
Inclusion
- Normal MRI scan
- Body mass index 19-30 kg/m2 and weight of 50-100 kg
- Clinically normal physical findings, medical history and laboratory values
Exclusion
- Trauma or sickness last 2 weeks before the first PET examination.
- A history or presence of neurological, haematological, psychiatric, gastrointestinal, hepatic, pulmonary, renal disease or other condition as judged by the Investigator
- Any previous participation in a PET study
- Subjects suffer from claustrophobia
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00832221
Start Date
January 1 2009
End Date
September 1 2009
Last Update
September 14 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Stockholm, Sweden